RecruitingType 2 Diabetes Mellitus

A Study to Find Out if the Study Drug Elecoglipron Helps Adults With Type 2 Diabetes Mellitus by Comparing it With Semaglutide, a Medicine Already Used to Treat Type 2 Diabetes Mellitus

Eligible age

18+ yrs

Accepts

All genders

Locations

30 states

Healthy volunteers

See if you qualify for this study

Answer a few quick questions about your location and health. Takes about a minute.

Check my eligibility →

About this study

The purpose of this study is to evaluate the efficacy, safety, and tolerability of elecoglipron compared with oral semaglutide in adults with T2DM and increased cardiovascular risk that is inadequately managed alone or on stable treatment with other background glucose-lowering medication(s).

Sponsor: AstraZeneca

You may qualify if…

✓ Diagnosed with Type 2 Diabetes Mellitus (T2DM) for at least 90 days prior to screening
✓ T2DM inadequately managed with lifestyle management alone or on stable treatment with other background glucose-lowering medication(s)
✓ HbA1c value of ≥ 7% to ≤ 10.5% (53 to 91.3 mmol/mol)
✓ Increased risk of cardiovascular (CV) events defined by ≥1 of: documented coronary heart disease, peripheral arterial disease, ischemic cerebrovascular disease, or heart failure (NYHA II-III); or ≥2 CV risk factors
✓ Body mass index (BMI) of ≥ 23 kg/m2 at screening
✓ Stable body weight (self-reported or documented) for 90 days prior to screening

You may not qualify if…

✕ Type 1 Diabetes Mellitus (T1DM), secondary forms of diabetes (including congenital forms), or history of ketoacidosis or hyperosmolar coma
✕ Currently receiving or anticipated to receive, therapeutic intervention for diabetic retinopathy and/or macular edema
✕ Have had more than one episode of severe hypoglycemia within 180 days prior to screening or has a history of hypoglycemia unawareness or poor recognition of hypoglycemic symptoms
✕ Clinically significant condition affecting the upper Gastrointestinal (GI) tract or chronic use of any medication that affects gastric motility or gastric emptying
✕ History of acute or chronic pancreatitis
✕ Severe congestive heart failure (NYHA IV)
✕ History/family history of medullary thyroid cancer or multiple endocrine neoplasia type 2